Lv4
570 积分 2021-04-30 加入
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
1个月前
已完结
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
1个月前
已完结
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
1个月前
已完结
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
1个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
2个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已关闭
Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage small-cell lung cancer: results of a phase Ib clinical trial
5个月前
已关闭
Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage small-cell lung cancer: results of a phase Ib clinical trial
6个月前
已关闭
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
6个月前
已完结
皖公网安备34019202002308
